Mission Therapeutics (Biotechnology, Health Care) — Funding, Investors & Signals 2026

Mission Therapeutics

Founded 2011

Cambridge, United Kingdom 34 employees Grant Total: $133.80M Biotechnology, Health Care +2

Mission Therapeutics is a private, drug discovery and development company based in the United Kingdom, founded in 2011. The company is dedicated to selectively targeting deubiquitylating enzymes to address diseases with high unmet medical needs. Mission has succeeded in building a leading platform for the discovery and development of first-in-class, small-molecule drugs that selectively target deubiquitylating enzymes (DUBs). This innovative approach is gaining significant commercial interest and is considered as the potential 'Next Kinase Area.' The company's strategic emphasis lies in advancing its pipeline programs through early clinical development, with a preference for a patient selection strategy to enhance the probability of demonstrating early signs of efficacy. Mission's leadership team brings a wealth of international, commercial, and scientific experience, and the company has fostered strong collaborations with key academic and research centers such as Cancer Research UK Laboratories and the Jackson Laboratories at the Gurdon Institute, University of Cambridge. Mission Therapeutics has received a total of £87 million in venture capital from a prestigious syndicate including institutional and corporate investors. Additionally, the company was granted £1.9 million from Innovate UK in September 2015. In February 2016, Mission raised £60 million in a Series C financing round led by Imperial Innovations and new investor Woodford Patient Capital Trust, with follow-on investments from existing shareholders including Sofinnova Partners, SR One, Roche Venture Fund, and Pfizer Venture Investments. The company continues to make notable progress and is located at the Babraham Research Campus, south of Cambridge. Mission Therapeutics is primed to make a significant impact across biotechnology and healthcare sectors with its rich pipeline of novel therapeutics for the benefit of patients across therapeutic areas.

Funding Stage	Amount	Investors	Lead Investors	Date
Grant	••••••	2	•••• ••••	02 Jul 2024
Series D	••••••	6	•••• ••••	14 Mar 2024
Grant	••••••	1		12 Oct 2021
Series C	••••••	7	•••• ••••	06 Jul 2020
Grant	••••••	1		11 Apr 2017

Funding Stage

Amount

Investors

Lead Investors

Date

Grant

••••••

•••• ••••

02 Jul 2024

Series D

••••••

•••• ••••

14 Mar 2024

Grant

••••••

12 Oct 2021

Series C

••••••

•••• ••••

06 Jul 2020

Grant

••••••

11 Apr 2017

FAQ About Mission Therapeutics

Mission Therapeutics is a private, drug discovery and development company focused on selectively targeting deubiquitylating enzymes to treat diseases of high unmet need. Mission has built a world-leading platform for the discovery and development of first-in-class, small-molecule drugs that selec...

Mission Therapeutics was founded in 2011.

Mission Therapeutics is headquartered in Cambridge, United Kingdom.

Mission Therapeutics operates in the following industries: Biotechnology, Health Care, Health and Wellness, Life Sciences.

Mission Therapeutics has approximately 34 employees.

Mission Therapeutics has completed 9 funding rounds, raising a total of $133.80M. The latest funding stage is Grant.

Top alternatives and competitors to Mission Therapeutics include STORM Therapeutics Limited, TVM Capital Life Science, Apollo Therapeutics, Atomwise, Pheon Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Mission Therapeutics and STORM Therapeutics Limited are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Mission Therapeutics

General Information

Track Mission Therapeutics

Discover More

About Mission Therapeutics

Funding Rounds & Investors (9)

Latest News

Mission Therapeutics Alternatives & Competitors

FAQ About Mission Therapeutics

Don't just browse. Track.